An LC-MS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes

Drug and Alcohol Dependence

Volumn 125, Issue 1-2, 2012, Pages 49-59

  Ande, Anusha ^a   Earla, Ravinder ^a   Jin, Mengyao ^a   Silverstein, Peter S ^a   Mitra, Ashim K ^a   Kumar, Anil ^a   Kumar, Santosh ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Astrocytes; CYP2A6; LC MS MS; Nicotine; Oxidative stress

Indexed keywords

COTININE; CYTOCHROME P450 1A1; CYTOCHROME P450 2A6; KETONE DERIVATIVE; MESSENGER RNA; NICOTINE; NICOTINE DERIVED NITROSAMINE KETONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRYPTAMINE; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTE; CELL IMMORTALIZATION; CONTROLLED STUDY; CYP1A1 GENE; CYP2A6 GENE; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; METABOLITE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ARYL HYDROCARBON HYDROXYLASES; ASTROCYTES; BLOTTING, WESTERN; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COTININE; CYTOCHROME P-450 CYP1A1; ENZYME INDUCTION; HUMANS; KETONES; LIMIT OF DETECTION; NICOTINE; NICOTINIC AGONISTS; NITROSAMINES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA; TANDEM MASS SPECTROMETRY;

EID: 84864977581     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.03.015     Document Type: Article

References (44)

1. Abbud R.A., Finegan C.K., Guay L.A., Rich E.A. Enhanced production of human immunodeficiency virus type 1 by in vitro-infected alveolar macrophages from otherwise healthy cigarette smokers. J. Infect. Dis. 1995, 172:859-863.
2. Aquaro S., Ronga L., Pollicita M., Antinori A., Ranazzi A., Perno C.F. Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: role of cells of monocyte-macrophage lineage. J. Neurovirol. 2005, 11(Suppl. 3):58-66.
3. Benowitz N.L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 2009, 49:57-71.
4. Bhagwat S.V., Vijayasarathy C., Raza H., Mullick J., Avadhani N.G. Preferential effects of nicotine and 4-(N-methyl-N-nitrosamine)-1-(3-pyridyl)-1-butanone on mitochondrial glutathione S-transferase A4-4 induction and increased oxidative stress in the rat brain. Biochem. Pharmacol. 1998, 56:831-839.
5. Boelaert J.R., Piette J., Weinberg G.A., Sappey C., Weinberg E.D. Iron and oxidative stress as a mechanism for the enhanced production of human immunodeficiency virus by alveolar macrophages from otherwise healthy cigarette smokers. J. Infect. Dis. 1996, 173:1045-1047.
6. Burkhalter J.E., Springer C.M., Chhabra R., Ostroff J.S., Rapkin B.D. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob. Res. 2005, 7:511-522.
7. Byrd G.D., Davis R.A., Ogden M.W. A rapid LC-MS-MS method for the determination of nicotine and cotinine in serum and saliva samples from smokers: validation and comparison with a radioimmunoassay method. J. Chromatogr. Sci. 2005, 43:133-140.
8. Byrd G.D., Ogden M.W. Liquid chromatographic/tandem mass spectrometric method for the determination of the tobacco-specific nitrosamine metabolite NNAL in smokers' urine. J. Mass Spectrom. 2003, 38:98-107.
9. Chuang C.H., Hu M.L. Synergistic DNA damage and lipid peroxidation in cultured human white blood cells exposed to 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone and ultraviolet A. Environ. Mol. Mutagen. 2006, 47:73-81.
10. Demizu Y., Sasaki R., Trachootham D., Pelicano H., Colacino J.A., Liu J., Huang P. Alterations of cellular redox state during NNK-induced malignant transformation and resistance to radiation. Antioxid. Redox. Signal. 2008, 10:951-961.
11. Earla R., Boddu S.H., Cholkar K., Hariharan S., Jwala J., Mitra A.K. Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids-quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 52:525-533.
12. Feldman J.G., Minkoff H., Schneider M.F., Gange S.J., Cohen M., Watts D.H., Gandhi M., Mocharnuk R.S., Anastos K. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am. J. Public Health 2006, 96:1060-1065.
13. Ghosh D., Mishra M.K., Das S., Kaushik D.K., Basu A. Tobacco carcinogen induces microglial activation and subsequent neuronal damage. J. Neurochem. 2009, 110:1070-1081.
14. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91:1194-1210.
15. Hecht S.S., Hochalter J.B., Villalta P.W., Murphy S.E. 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12493-12497.
16. Jin M., Arya P., Patel K., Singh B., Silverstein P.S., Bhat H.K., Kumar A., Kumar S. Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. Alcohol. Clin. Exp. Res. 2011, 35:132-139.
17. Jin M., Earla R., Shah A., Earla R.L., Gupte R., Mitra A.K., Kumar A., Kumar S. A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: implications in oxidative stress in HIV + smokers. J. Neuroimmune Pharmacol. 2011, 7:289-299.
18. Johnson J.A., Johnson D.A., Kraft A.D., Calkins M.J., Jakel R.J., Vargas M.R., Chen P.C. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann. N.Y. Acad. Sci. 2008, 1147:61-69.
19. Joshi M., Tyndale R.F. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. Drug Metab. Dispos. 2006, 34:647-652.
20. Kadlubar S., Anderson J.P., Sweeney C., Gross M.D., Lang N.P., Kadlubar F.F., Anderson K.E. Phenotypic CYP2A6 variation and the risk of pancreatic cancer. JOP 2009, 10:263-270.
21. Khokhar J.Y., Miksys S.L., Tyndale R.F. Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. Brain Res. 2010, 1348:1-9.
22. Lee A.M., Miksys S., Palmour R., Tyndale R.F. CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology 2006, 50:441-450.
23. Lu Y., Zhuge J., Wu D., Cederbaum A.I. Ethanol induction of CYP2A5: permissive role for CYP2E1. Drug Metab. Dispos. 2011, 39:330-336.
24. Marclay F., Saugy M. Determination of nicotine and nicotine metabolites in urine by hydrophilic interaction chromatography-tandem mass spectrometry: potential use of smokeless tobacco products by ice hockey players. J. Chromatogr. A 2010, 1217:7528-7538.
25. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 1997, 282:1608-1614.
26. Miksys S., Hoffmann E., Tyndale R.F. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem. Pharmacol. 2000, 59:1501-1511.
27. Miksys S., Lerman C., Shields P.G., Mash D.C., Tyndale R.F. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003, 45:122-132.
28. Miksys S., Tyndale R.F. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J. Neural Transm. Suppl. 2006, 177-180.
29. Miller E.I., Norris H.R., Rollins D.E., Tiffany S.T., Wilkins D.G. A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2010, 878:725-737.
30. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 1996, 24:1212-1217.
31. Nakayama H., Okuda H., Nakashima T., Imaoka S., Funae Y. Nicotine metabolism by rat hepatic cytochrome P450s. Biochem. Pharmacol. 1993, 45:2554-2556.
32. Reddy P.V., Gandhi N., Samikkannu T., Saiyed Z., Agudelo M., Yndart A., Khatavkar P., Nair M.P. HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder. Neurochem. Int. 2011, (epub ahead of print).
33. Rock R.B., Gekker G., Aravalli R.N., Hu S., Sheng W.S., Peterson P.K. Potentiation of HIV-1 expression in microglial cells by nicotine: involvement of transforming growth factor-beta 1. J. Neuroimmune Pharmacol. 2008, 3:143-149.
34. Rodriguez-Antona C., Donato M.T., Boobis A., Edwards R.J., Watts P.S., Castell J.V., Gomez-Lechon M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002, 32:505-520.
35. Savarino A., Pescarmona G.P., Boelaert J.R. Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences?. Cell. Biochem. Funct. 1999, 17:279-287.
36. Smith T.J., Stoner G.D., Yang C.S. Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res. 1995, 55:5566-5573.
37. Sopori M.L., Kozak W., Savage S.M., Geng Y., Kluger M.J. Nicotine-induced modulation of T Cell function. Implications for inflammation and infection. Adv. Exp. Med. Biol. 1998, 437:279-289.
38. Steele M.L., Robinson S.R. Reactive astrocytes give neurons less support: implications for Alzheimer's disease. Neurobiol. Aging 2012, 33:423. e421-423, e413.
39. Vargas M.R., Johnson J.A. The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev. Mol. Med. 2009, 11:e17.
40. Wong H.L., Zhang X., Zhang Q.Y., Gu J., Ding X., Hecht S.S., Murphy S.E. Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes. Chem. Res. Toxicol. 2005, 18:913-918.
41. Yokota S., Higashi E., Fukami T., Yokoi T., Nakajima M. Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem. Pharmacol. 2011, 81:289-294.
42. Zhang W., Kilicarslan T., Tyndale R.F., Sellers E.M. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos. 2001, 29:897-902.
43. Zhang X., D'Agostino J., Wu H., Zhang Q.Y., von Weymarn L., Murphy S.E., Ding X. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 2007, 323:570-578.
44. Zhou X., Zhuo X., Xie F., Kluetzman K., Shu Y.Z., Humphreys W.G., Ding X. Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. J. Pharmacol. Exp. Ther. 2010, 332:578-587.